Huang Grace, Melki Samir
Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Boston Eye Group, Brookline, MA, USA.
Semin Ophthalmol. 2021 May 19;36(4):140-148. doi: 10.1080/08820538.2021.1887897. Epub 2021 Apr 6.
The emergence of SMILE in the last decade has provided an alternative to LASIK for patients considering cornea laser refractive surgery. SMILE offers a novel approach using the femtosecond laser to create an intrastromal lenticule that can be removed through a small three to four millimeter incision.The purpose of this study is to review the recent literature on popular SMILE claims - reduced iatrogenic dry eye, better recovery of corneal sensation, and a biomechanically stronger cornea - summarize the published outcomes, and determine which claims are myths versus realities.SMILE is still in its infancy as a refractive technique in the US after recent USFDA approval for its treatment of myopia astigmatism in October 2018. Future randomized controlled studies are needed to compare its outcomes to LASIK, which has well-documented good visual outcomes, rapid postoperative recovery, and good safety profile.
在过去十年中,全飞秒激光微小切口基质透镜切除术(SMILE)的出现为考虑进行角膜激光屈光手术的患者提供了一种替代准分子原位角膜磨镶术(LASIK)的选择。SMILE提供了一种新颖的方法,即使用飞秒激光制作一个基质内透镜,该透镜可通过三到四毫米的小切口取出。本研究的目的是回顾近期关于SMILE的热门说法——减少医源性干眼、角膜感觉更好恢复以及角膜生物力学更强——总结已发表的结果,并确定哪些说法是误区,哪些是事实。在美国,SMILE作为一种屈光技术仍处于起步阶段,2018年10月美国食品药品监督管理局(USFDA)最近批准其用于治疗近视散光。未来需要进行随机对照研究,以将其结果与LASIK进行比较,LASIK具有良好的视觉效果、快速的术后恢复和良好的安全性记录。